Anlysis of Bio - Pharma in East Asia - Trends Report
Biopharmaceutical Report III Issue6_April 2015 Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic...
Search
Astellas/Medivation's Xtandi has questionable potential to displace bicalutamide
Biopharmaceutical Report II Issue6_April 2015 Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on...
Spark's LCA2 gene therapy is likely to have greater benefit for younger patients
Biopharmaceutical Report I Issue6_April 2015 Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely...
Biosimilar Reference Products Expected to Grow
Biopharmaceutical Report II Issue5_February 2015 • Logistic complications create high demand for the expertise of comparator suppliers •...
Diabetic Neuropathy Patient Stratification, Chances Boosted
Biopharmaceutical Report I Issue5_February 2015 • Phase II signals encouraging for positive Phase III translation • Capsaicin as...
J&J may suffer over AbbVie,Amgen in renewed biologic USpayer contracts as Celltrion’sbiosimilar loom
Biopharmaceutical Report II Issue4_November 2014 • Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • ...
Array/Novartis’ binimetinib expected to best chemotherapy in Phase III trial despite protocol change
Biopharmaceutical Report I Issue4_November 2015 • Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • ...
The Unrealized Potential of Stem Cell Therapy
Biopharmaceutical Report III Issue3_September 2014 Over the last decade or so, I have observed a tempering of what was once a large and...
*Novartis’ LCZ696 for CHFdraws approval optimism aftermeeting difficult Phase IIIendpoints
Biopharmaceutical Report II Issue3_September 2014 • Superiority to standard therapy bodes well for approvals • Regulators may require...
*Celgene's Revlimid has experts optimistic about potential in Phase III non-del (5q) MDS trial in tr
Biopharmaceutical Report I Issue3_September 2014 • Historical responses meaningful, but approvability based on transfusion changes...